Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus

Bibliographische Detailangaben

Veröffentlicht in:	MedChemComm 2011-09, Vol.2 (9), p.828
Hauptverfasser:	Pfefferkorn, Jeffrey A., Guzman-Perez, Angel, Oates, Peter J., Litchfield, John, Aspnes, Gary, Basak, Arindrajit, Benbow, John, Berliner, Martin A., Bian, Jianwei, Choi, Chulho, Freeman-Cook, Kevin, Corbett, Jeffrey W., Didiuk, Mary, Dunetz, Joshua R., Filipski, Kevin J., Hungerford, William M., Jones, Christopher S., Karki, Kapil, Ling, Anthony, Li, Jian-Cheng, Patel, Leena, Perreault, Christian, Risley, Hud, Saenz, James, Song, Wei, Tu, Meihua, Aiello, Robert, Atkinson, Karen, Barucci, Nicole, Beebe, David, Bourassa, Patricia, Bourbounais, Francis, Brodeur, Anne M., Burbey, Rena, Chen, Jing, D'Aquila, Theresa, Derksen, David R., Haddish-Berhane, Nahor, Huang, Cong, Landro, James, Lee Lapworth, Amanda, MacDougall, Margit, Perregaux, David, Pettersen, John, Robertson, Alan, Tan, Beijing, Treadway, Judith L., Liu, Shenping, Qiu, Xiayang, Knafels, John, Ammirati, Mark, Song, Xi, DaSilva-Jardine, Paul, Liras, Spiros, Sweet, Laurel, Rolph, Timothy P.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!